Re: V.I. Avramis et al., Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a Phase I/II study in pediatric patients with relapsed leukemias. Clin. Cancer Res., 4: 45-52, 1998. Fludarabine: phosphate or no phosphate, that is the confusion.
A G
AG
Bosanquet
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D009626:Terminology as Topic; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001084:Vidarabine Phosphate / Q000008:administration & dosage / Q000031:analogs & derivatives
D003561:Cytarabine; D001084:Vidarabine Phosphate; C042382:fludarabine phosphate; D014740:Vidarabine; C024352:fludarabine